Lipocine Inc. 8-K

What Happened

• On April 2, 2026, Lipocine Inc. (LPCN) filed a Form 8-K (Item 8.01) and issued a press release reporting topline safety and efficacy results for LPCN-1154 in patients with postpartum depression. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: April 2, 2026 (Form 8-K, Item 8.01).
• Program: LPCN-1154 — investigational treatment for postpartum depression.
• Announcement: Topline safety and efficacy results were reported (details provided in the press release filed as Exhibit 99.1).
• Exhibit included: Press release (Exhibit 99.1) was attached to the 8-K.

Why It Matters

• Topline safety and efficacy results are a key clinical milestone that can influence investor perception of Lipocine’s development progress for LPCN-1154.
• Investors should watch for the full data release, regulatory updates, or follow-up disclosures from the company, which will provide the detailed results needed to assess clinical and commercial prospects.